Literature DB >> 4979953

The pathogenesis of Aleutian disease of mink. I. In vivo viral replication and the host antibody response to viral antigen.

D D Porter, A E Larsen, H G Porter.   

Abstract

Mink inoculated with 1 x 10(5)ID(50) of Aleutian disease virus revealed very high virus titers in the tissues 8-18 days later. The highest virus titers observed were 5 x 10(8)ID(50) per g of spleen and 1 x 10(9)ID(50) per g of liver 10 days after inoculation. Concomitant with the increase in infectious virus titers, viral antigen(s) was found in the cytoplasm of macrophages in the spleen and lymph nodes and in Kupffer cells in the liver. Antiviral antibody was assayed by indirect immunofluorescence, using sections of infected liver as the source of antigen. A few mink infected for 9 days and all those infected 10 days or more developed antibody to Aleutian disease virus antigen(s). By 60 days after infection, when hypergammaglobulinemia was marked, the mink had an exceptionally high mean antibody titer of 100,000. The pathogenesis of the glomerulonephritis of Aleutian disease is apparently related to formation of viral antigen-antibody-complement complexes which lodge in glomerular capillaries. No evidence was found that viral infection of the kidney took place, and no autoimmune responses were found. In this "slow-virus" disease the virus replicates rapidly and the morphologic and biochemical manifestations of disease are apparently due to the continuing interplay between a replicating antigen and the host immune response.

Entities:  

Mesh:

Year:  1969        PMID: 4979953      PMCID: PMC2138710          DOI: 10.1084/jem.130.3.575

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  STATISTICAL SURVEY OF ALEUTIAN DISEASE IN RANCH MINK.

Authors:  D D PORTER; A E LARSEN
Journal:  Am J Vet Res       Date:  1964-07       Impact factor: 1.156

2.  THE DEVELOPMENT OF A MYELOMA-LIKE CONDITION IN MINK WITH ALEUTIAN DISEASE.

Authors:  D D PORTER; F J DIXON; A E LARSEN
Journal:  Blood       Date:  1965-05       Impact factor: 22.113

Review 3.  LACTIC DEHYDROGENASE VIRUS.

Authors:  A L NOTKINS
Journal:  Bacteriol Rev       Date:  1965-06

4.  MOUSE BETA-1C-GLOBULIN: PRODUCTION OF ANTISERUM AND CHARACTERIZATION IN THE COMPLEMENT REACTION.

Authors:  M R MARDINEY; H J MUELLER-EBERHARD
Journal:  J Immunol       Date:  1965-06       Impact factor: 5.422

5.  Characterization of blood serum proteins from mink with Aleutian disease.

Authors:  A J KENYON; G TRAUTWEIN; C F HELMBOLDT
Journal:  Am J Vet Res       Date:  1963-01       Impact factor: 1.156

6.  Aleutian disease of mink: properties of the etiologic agent and the host responses.

Authors:  C M Eklund; W J Hadlow; R C Kennedy; C C Boyle; T A Jackson
Journal:  J Infect Dis       Date:  1968-12       Impact factor: 5.226

7.  Pathogenesis of the glomerular lesions in aleutian disease of mink. Immunofluorescent studies.

Authors:  J B Henson; J R Gorham; G A Padgett; W C Davis
Journal:  Arch Pathol       Date:  1969-01

8.  Studies on the mechanism of action of Riley virus. 3. Replication of Riley's plasma enzyme-elevating virus in vitro.

Authors:  R Evans; M H Salaman
Journal:  J Exp Med       Date:  1965-11-01       Impact factor: 14.307

9.  Chemotoxis of mononuclear cells.

Authors:  P A Ward
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

10.  Infectious virus-antibody complex in the blood of chronically infected mice.

Authors:  A L Notkins; S Mahar; C Scheele; J Goffman
Journal:  J Exp Med       Date:  1966-07-01       Impact factor: 14.307

View more
  107 in total

1.  Poly IC therapy in aleutian disease of mink.

Authors:  A S Russell; J S Percy; H J Cho
Journal:  Can J Comp Med       Date:  1975-07

Review 2.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

3.  Nucleotide sequence analysis of Aleutian mink disease parvovirus shows that multiple virus types are present in infected mink.

Authors:  E Gottschalck; S Alexandersen; A Cohn; L A Poulsen; M E Bloom; B Aasted
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  The transcription profile of Aleutian mink disease virus in CRFK cells is generated by alternative processing of pre-mRNAs produced from a single promoter.

Authors:  Jianming Qiu; Fang Cheng; Lisa R Burger; David Pintel
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Replication of Aleutian mink disease parvovirus in lymphoid tissues of adult mink: involvement of follicular dendritic cells and macrophages.

Authors:  S Mori; J B Wolfinbarger; M Miyazawa; M E Bloom
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

6.  Eradication of Aleutian disease of mink by eliminating positive counterimmunoelectrophoresis test reactors.

Authors:  H J Cho; J Greenfield
Journal:  J Clin Microbiol       Date:  1978-01       Impact factor: 5.948

7.  Analysis of Aleutian disease virus infection in vitro and in vivo: demonstration of Aleutian disease virus DNA in tissues of infected mink.

Authors:  M E Bloom; R E Race; B Aasted; J B Wolfinbarger
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

8.  Identification of aleutian mink disease parvovirus capsid sequences mediating antibody-dependent enhancement of infection, virus neutralization, and immune complex formation.

Authors:  M E Bloom; S M Best; S F Hayes; R D Wells; J B Wolfinbarger; R McKenna; M Agbandje-McKenna
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Myeloid depression follows infection of susceptible newborn mice with the parvovirus minute virus of mice (strain i).

Authors:  J C Segovia; J A Bueren; J M Almendral
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Pathogenesis of aleutian disease of mink: nature of the antiglobulin reaction and elution of antibody from erythrocytes and glomeruli of infected mink.

Authors:  H J Cho; D G Ingram
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.